Literature DB >> 31935285

von Willebrand factor binding to myosin assists in coagulation.

Veronica H Flood1,2,3, Tricia L Slobodianuk1, Daniel Keesler3, Hannah K Lohmeier3, Scot Fahs1, Liyun Zhang4, Pippa Simpson4, Robert R Montgomery1,2,3.   

Abstract

von Willebrand factor (VWF) binds to platelets and collagen as a means of facilitating coagulation at sites of injury. Recent evidence has shown that myosin can serve as a surface for thrombin generation and binds to activated factor V and factor X. We studied whether VWF can also bind myosin as a means of bringing factor VIII (FVIII) to sites of clot formation. A myosin-binding assay was developed using skeletal muscle myosin to measure VWF binding, and plasma-derived and recombinant VWF containing molecular disruptions at key VWF sites were tested. Competition assays were performed using anti-VWF antibodies. FVIII binding to myosin was measured using a chromogenic FVIII substrate. Thrombin generation was measured using a fluorogenic substrate with and without myosin. Wild-type recombinant VWF and human plasma VWF from healthy controls bound myosin, whereas plasma lacking VWF exhibited no detectable myosin binding. Binding was multimer dependent and blocked by anti-VWF A1 domain antibodies or A1 domain VWF variants. The specific residues involved in myosin binding were similar, but not identical, to those required for collagen IV binding. FVIII did not bind myosin directly, but FVIII activity was detected when VWF and FVIII were bound to myosin. Myosin enhanced thrombin generation in platelet-poor plasma, although no difference was detected with the addition of myosin to platelet-rich plasma. Myosin may help to facilitate delivery of FVIII to sites of injury and indirectly accelerate thrombin generation by providing a surface for VWF binding in the setting of trauma and myosin exposure.
© 2020 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31935285      PMCID: PMC6960459          DOI: 10.1182/bloodadvances.2019000533

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  28 in total

1.  Critical von Willebrand factor A1 domain residues influence type VI collagen binding.

Authors:  V H Flood; J C Gill; P A Christopherson; D B Bellissimo; K D Friedman; S L Haberichter; S R Lentz; R R Montgomery
Journal:  J Thromb Haemost       Date:  2012-07       Impact factor: 5.824

2.  The arginine-552-cysteine (R1315C) mutation within the A1 loop of von Willebrand factor induces an abnormal folding with a loss of function resulting in type 2A-like phenotype of von Willebrand disease: study of 10 patients and mutated recombinant von Willebrand factor.

Authors:  A N Ribba; L Hilbert; J M Lavergne; E Fressinaud; C Boyer-Neumann; C Ternisien; I Juhan-Vague; J Goudemand; J Girma; C Mazurier; D Meyer
Journal:  Blood       Date:  2001-02-15       Impact factor: 22.113

3.  Targeting FVIII expression to endothelial cells regenerates a releasable pool of FVIII and restores hemostasis in a mouse model of hemophilia A.

Authors:  Qizhen Shi; Scot A Fahs; Erin L Kuether; Brian C Cooley; Hartmut Weiler; Robert R Montgomery
Journal:  Blood       Date:  2010-07-06       Impact factor: 22.113

4.  Localization of von willebrand factor-binding sites for platelet glycoprotein Ib and botrocetin by charged-to-alanine scanning mutagenesis.

Authors:  T Matsushita; D Meyer; J E Sadler
Journal:  J Biol Chem       Date:  2000-04-14       Impact factor: 5.157

5.  Identification of patients at low risk for recurrent venous thromboembolism by measuring thrombin generation.

Authors:  Gregor Hron; Marietta Kollars; Bernd R Binder; Sabine Eichinger; Paul A Kyrle
Journal:  JAMA       Date:  2006-07-26       Impact factor: 56.272

6.  Different bleeding risk in type 2A and 2M von Willebrand disease: a 2-year prospective study in 107 patients.

Authors:  G Castaman; A B Federici; A Tosetto; S La Marca; F Stufano; P M Mannucci; F Rodeghiero
Journal:  J Thromb Haemost       Date:  2012-04       Impact factor: 5.824

7.  The von Willebrand factor D'D3 assembly and structural principles for factor VIII binding and concatemer biogenesis.

Authors:  Xianchi Dong; Nina C Leksa; Ekta Seth Chhabra; Joseph W Arndt; Qi Lu; Kevin E Knockenhauer; Robert T Peters; Timothy A Springer
Journal:  Blood       Date:  2019-01-14       Impact factor: 22.113

8.  Abnormal hemostasis in a knock-in mouse carrying a variant of factor IX with impaired binding to collagen type IV.

Authors:  T Gui; A Reheman; H Ni; P L Gross; F Yin; D Monroe; P E Monahan; D W Stafford
Journal:  J Thromb Haemost       Date:  2009-07-06       Impact factor: 5.824

9.  Performance evaluation and multicentre study of a von Willebrand factor activity assay based on GPIb binding in the absence of ristocetin.

Authors:  Juergen Patzke; Ulrich Budde; Andreas Huber; Adriana Méndez; Heidrun Muth; Tobias Obser; Ellinor Peerschke; Matthias Wilkens; Reinhard Schneppenheim
Journal:  Blood Coagul Fibrinolysis       Date:  2014-12       Impact factor: 1.276

Review 10.  The evolving understanding of factor VIII binding sites and implications for the treatment of hemophilia A.

Authors:  Gary E Gilbert
Journal:  Blood Rev       Date:  2018-05-24       Impact factor: 8.250

View more
  3 in total

Review 1.  Novel blood coagulation molecules: Skeletal muscle myosin and cardiac myosin.

Authors:  Hiroshi Deguchi; Shravan Morla; John H Griffin
Journal:  J Thromb Haemost       Date:  2020-10-25       Impact factor: 5.824

2.  Fibronectin binding to von Willebrand factor occurs via the A1 domain.

Authors:  Daniel A Keesler; Tricia L Slobodianuk; Caroline E Kochelek; Chad W Skaer; Sandra L Haberichter; Veronica H Flood
Journal:  Res Pract Thromb Haemost       Date:  2021-06-05

3.  Skeletal muscle myosin and cardiac myosin attenuate heparin's antithrombin-dependent anticoagulant activity.

Authors:  Shravan Morla; Hiroshi Deguchi; John H Griffin
Journal:  J Thromb Haemost       Date:  2020-12-10       Impact factor: 5.824

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.